Latest Form 144 filings
Officers, directors and other affiliates of a company file Form 144 when they place an order to sell restricted or control shares, if they plan to sell more than 5,000 shares or more than $50,000 worth within three months. It is a notice of a planned sale; officers and directors report the sale itself later on Form 4. 13D, 13G and Form 144 explained
Form 144 notices
Newest first. When a Form 144/A amends a notice, only the amendment is listed.
Filed in the last 365 days (US Eastern dates).
Form 144 filings on Livermore: Jan 4, 2023 to Sep 29, 2026.
Notices with a clearly misreported market value are left out of this list and its totals; they still appear, flagged, on the company's page. A value counts as misreported when the price per share it implies is far above the company's prices in Form 4 trades and 13F filings around the planned sale date.
- Notices
- 17
- Market value to sell
- $52.2M
- Sellers
- 8
- Companies
- 2
- Under 10b5-1 plans
- 15
| Company | Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals, Inc. | Sep 3, 20264:07 PM ET | McCourt MarionOfficer | 1.13K | $969.3K | Sep 3, 202610b5-1 | UBS Financial Services Inc. | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Sep 2, 20264:11 PM ET | McCourt MarionOfficer | 1.22K | $1.03M | Sep 2, 202610b5-1 | UBS Financial Services Inc. | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Sep 2, 20264:09 PM ET | Guarini KathrynDirector | 400 | $340.0K | Sep 2, 202610b5-1 | UBS Financial Services, Inc. | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Aug 10, 20264:14 PM ET | Zoghbi Huda YDirector | 800 | $640.0K | Aug 10, 202610b5-1 | UBS Financial Services, Inc. | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Aug 10, 20264:11 PM ET | Guarini KathrynBoard member | 400 | $320.0K | Aug 10, 202610b5-1 | UBS Financial Services, Inc. | SEC |
| TTTrane Technologies plc | Aug 5, 20264:04 PM ET | Regnery David SOfficer · Director | 43.8K | $20.8M | Aug 5, 202610b5-1 | UBS Financial Services, Inc | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Jul 2, 20265:46 PM ET | Arthur F. RyanDirector | 400 | $249.9K | Jul 2, 202610b5-1 | J.P. Morgan Securities LLC | SEC |
| TTTrane Technologies plc | Mar 6, 20264:12 PM ET | Regnery David SOfficer · Director | 36.0K | $15.4M | Mar 6, 202610b5-1 | UBS Financial Services, Inc | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Feb 19, 20264:04 PM ET | Zoghbi Huda YDirector | 1.64K | $1.29M | Feb 19, 202610b5-1 | UBS Financial Services, Inc. | SEC |
| TTTrane Technologies plc | Feb 10, 20264:03 PM ET | Regnery David SOfficer · Director | 5.59K | $2.57M | Feb 10, 202610b5-1 | UBS Financial Services, Inc | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Feb 9, 20265:02 PM ET | Arthur F. RyanDirector | 400 | $314.2K | Feb 9, 202610b5-1 | J.P. Morgan Securities LLC | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Feb 9, 20264:03 PM ET | Pitofsky JasonOfficer | 2.04K | $1.59M | Feb 9, 202610b5-1 | UBS Financial Services, Inc. | SEC |
| TTTrane Technologies plc | Feb 6, 20264:10 PM ET | Regnery David SOfficer | 987 | $438.9K | Feb 6, 202610b5-1 | UBS Financial Services, Inc | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Jan 7, 202612:03 PM ET | Bassler Bonnie LDirector | 1.50K | $1.20M | Jan 7, 202610b5-1 | RBC CAPITAL MARKETS LLC | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Nov 20, 20252:31 PM ET | Bassler Bonnie LDirector | 760 | $570.0K | Nov 20, 202510b5-1 | RBC CAPITAL MARKETS LLC | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Nov 7, 20255:06 PM ET | Jason PitofskyOfficer | 431 | $280.6K | Nov 7, 2025 | UBS Financial Services Inc | SEC |
| REGNRegeneron Pharmaceuticals, Inc. | Oct 29, 20254:36 PM ET | Christine PoonDirector | 6.50K | $4.24M | Oct 29, 2025 | Goldman Sachs & Co. LLC | SEC |